$EKSO
EKSO BIONICS HOLDINGS, INC. Stock $ekso

$ekso Overview Financials Valuation SEC Filings Company Website

2019 Q4 Form 10-Q Financial Statement

#000154908419000007 Filed on October 30, 2019

Income Statement

Concept	2019 Q4	2019 Q3	2018 Q4
Revenue	$3.720M	$3.319M	$3.300M
YoY Change	12.73%	30.16%	34.53%
Cost Of Revenue	$1.870M	$1.569M	$1.810M
YoY Change	3.31%	6.95%	7.74%
Gross Profit	$1.860M	$1.750M	$1.490M
YoY Change	24.83%	61.59%	91.76%
Gross Profit Margin	50.0%	52.73%	45.15%
Selling, General & Admin	$4.110M	$4.391M	$5.290M
YoY Change	-22.31%	-25.46%	-23.11%
% of Gross Profit	220.97%	250.91%	355.03%
Research & Development	$560.0K	$1.149M	$1.370M
YoY Change	-59.12%	-10.37%	-31.16%
% of Gross Profit	30.11%	65.66%	91.95%
Depreciation & Amortization	$170.0K	$30.00K	$350.0K
YoY Change	-51.43%	-89.29%	-18.6%
% of Gross Profit	9.14%	1.71%	23.49%
Operating Expenses	$4.690M	$5.540M	$6.630M
YoY Change	-29.26%	-22.81%	-24.05%
Operating Profit	-$2.830M	-$3.790M	-$5.140M
YoY Change	-44.94%	-37.81%	-35.37%
Interest Expense	-$70.00K	$88.00K	-$130.0K
YoY Change	-46.15%	-39.31%	-66.67%
% of Operating Profit
Other Income/Expense, Net	$190.0K	$3.996M	$1.140M
YoY Change	-83.33%	-549.49%	-275.38%
Pretax Income	-$2.720M	$210.0K	-$4.130M
YoY Change	-34.14%	-103.01%	-54.01%
Income Tax
% Of Pretax Income
Net Earnings	-$2.720M	$206.0K	-$4.130M
YoY Change	-34.14%	-102.95%	-54.0%
Net Earnings / Revenue	-73.12%	6.21%	-125.15%
Basic Earnings Per Share		$0.04
Diluted Earnings Per Share	-$531.3K	$0.04	-$988.0K
COMMON SHARES
Basic Shares Outstanding	74.95M shares	4.996M shares	62.64M shares
Diluted Shares Outstanding		4.997M shares

Balance Sheet

Concept	2019 Q4	2019 Q3	2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$10.87M	$8.060M	$7.660M
YoY Change	41.91%	-38.0%	-72.46%
Cash & Equivalents	$10.87M	$8.058M	$7.655M
Short-Term Investments
Other Short-Term Assets	$240.0K	$430.0K	$280.0K
YoY Change	-14.29%	-15.69%	-79.1%
Inventory	$2.489M	$3.342M	$3.371M
Prepaid Expenses
Receivables	$5.208M	$5.206M	$3.660M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$18.81M	$17.03M	$14.97M
YoY Change	25.66%	-14.2%	-57.16%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.657M	$1.723M	$2.365M
YoY Change	-29.94%	-20.6%	5.16%
Goodwill	$189.0K	$189.0K	$189.0K
YoY Change	0.0%	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$178.0K	$172.0K	$134.0K
YoY Change	32.84%	42.15%	9.84%
Total Long-Term Assets	$3.108M	$3.258M	$2.688M
YoY Change	15.63%	26.77%	-11.9%
TOTAL ASSETS
Total Short-Term Assets	$18.81M	$17.03M	$14.97M
Total Long-Term Assets	$3.108M	$3.258M	$2.688M
Total Assets	$21.92M	$20.29M	$17.66M
YoY Change	24.13%	-9.5%	-53.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.903M	$1.362M	$3.156M
YoY Change	-39.7%	-60.38%	30.41%
Accrued Expenses	$1.683M	$2.589M	$3.489M
YoY Change	-51.76%	-25.37%	-0.4%
Deferred Revenue	$1.492M	$1.398M	$1.102M
YoY Change	35.39%	47.94%	-0.09%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.333M	$2.333M	$2.333M
YoY Change	0.0%	0.0%	9.07%
Total Short-Term Liabilities	$7.832M	$8.087M	$10.08M
YoY Change	-22.3%	-20.6%	9.98%
LONG-TERM LIABILITIES
Long-Term Debt	$407.0K	$972.0K	$2.648M
YoY Change	-84.63%	-69.62%	-45.18%
Other Long-Term Liabilities	$72.00K	$17.00K	$119.0K
YoY Change	-39.5%	-37.04%	-13.77%
Total Long-Term Liabilities	$479.0K	$989.0K	$2.767M
YoY Change	-82.69%	-69.34%	-44.3%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.832M	$8.087M	$10.08M
Total Long-Term Liabilities	$479.0K	$989.0K	$2.767M
Total Liabilities	$15.12M	$13.87M	$14.93M
YoY Change	1.28%	-17.61%	-10.06%
SHAREHOLDERS EQUITY
Retained Earnings	-$183.3M	-$180.6M	-$171.1M
YoY Change	7.09%	8.11%	18.72%
Common Stock	$6.000K	$75.00K	$63.00K
YoY Change	-90.48%	19.05%	5.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$6.797M	$6.421M	$2.728M
YoY Change
Total Liabilities & Shareholders Equity	$21.92M	$20.29M	$17.66M
YoY Change	24.13%	-9.5%	-53.52%

Cashflow Statement

Concept	2019 Q4	2019 Q3	2018 Q4
OPERATING ACTIVITIES
Net Income	-$2.720M	$206.0K	-$4.130M
YoY Change	-34.14%	-102.95%	-54.0%
Depreciation, Depletion And Amortization	$170.0K	$30.00K	$350.0K
YoY Change	-51.43%	-89.29%	-18.6%
Cash From Operating Activities	-$1.490M	-$4.570M	-$5.160M
YoY Change	-71.12%	8.55%	-8.67%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	-$80.00K
YoY Change	-100.0%	-100.0%	-27.27%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	$0.00	-$80.00K
YoY Change	-100.0%	-100.0%	-27.27%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.270M	-600.0K	-110.0K
YoY Change	-3981.82%	-117.8%	-200.0%
NET CHANGE
Cash From Operating Activities	-1.490M	-4.570M	-5.160M
Cash From Investing Activities	0.000	0.000	-80.00K
Cash From Financing Activities	4.270M	-600.0K	-110.0K
Net Change In Cash	2.780M	-5.170M	-5.350M
YoY Change	-151.96%	501.16%	-5.31%
FREE CASH FLOW
Cash From Operating Activities	-$1.490M	-$4.570M	-$5.160M
Capital Expenditures	$0.00	$0.00	-$80.00K
Free Cash Flow	-$1.490M	-$4.570M	-$5.080M
YoY Change	-70.67%	9.07%	-8.3%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
	dei	Document Period End Date DocumentPeriodEndDate	2019-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001549084
CY2019Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	74952547	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	EKSO BIONICS HOLDINGS, INC.
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Small Business EntitySmallBusiness	true
CY2018Q4	ekso	Accrued Clinical Cost Current AccruedClinicalCostCurrent	227000	USD
CY2019Q3	ekso	Accrued Clinical Cost Current AccruedClinicalCostCurrent	301000	USD
CY2018Q3	ekso	Amortization Of Success Fee Expense AmortizationOfSuccessFeeExpense	9000	USD
	ekso	Amortization Of Success Fee Expense AmortizationOfSuccessFeeExpense	30000	USD
CY2019Q3	ekso	Amortization Of Success Fee Expense AmortizationOfSuccessFeeExpense	5000	USD
	ekso	Amortization Of Success Fee Expense AmortizationOfSuccessFeeExpense	19000	USD
CY2018Q3	ekso	Change In Fair Value Contingent Liabilities ChangeInFairValueContingentLiabilities	-4000	USD
	ekso	Change In Fair Value Contingent Liabilities ChangeInFairValueContingentLiabilities	11000	USD
CY2019Q3	ekso	Change In Fair Value Contingent Liabilities ChangeInFairValueContingentLiabilities	20000	USD
	ekso	Change In Fair Value Contingent Liabilities ChangeInFairValueContingentLiabilities	19000	USD
	ekso	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	1504000	shares
	ekso	Class Of Warrant Or Right Issued ClassOfWarrantOrRightIssued	6667000	shares
	ekso	Common Stock Contribution CommonStockContribution	156000	USD
	ekso	Common Stock Contribution CommonStockContribution	113000	USD
CY2019Q3	ekso	Contingent Success Fee Liability ContingentSuccessFeeLiability	15000	USD
	ekso	Contract With Customer Liability Deferral Of Revenue ContractWithCustomerLiabilityDeferralOfRevenue	2013000	USD
	ekso	Operating Leases Rent Expense Annual Incremental Percentage Increase OperatingLeasesRentExpenseAnnualIncrementalPercentageIncrease	0.03
CY2018Q1	ekso	Stock Issued During Period Value Equiposis Supply And Sales Earnouts StockIssuedDuringPeriodValueEquiposisSupplyAndSalesEarnouts	28000	USD
	ekso	Unrestricted Cash UnrestrictedCash	3686000	USD
	ekso	Operating Leases Right Of Use Asset Initial Recognition OperatingLeasesRightOfUseAssetInitialRecognition	1454000	USD
CY2018Q3	ekso	Other Income Expense OtherIncomeExpense	-63000	USD
	ekso	Other Income Expense OtherIncomeExpense	-338000	USD
CY2019Q3	ekso	Other Income Expense OtherIncomeExpense	-346000	USD
	ekso	Other Income Expense OtherIncomeExpense	-377000	USD
	ekso	Proceeds From Issuance Of Common Stock Preference Stock And Warrants ProceedsFromIssuanceOfCommonStockPreferenceStockAndWarrants	2313000	USD
	ekso	Sales Earnout SalesEarnout	28000	USD
	ekso	Sales Earnout SalesEarnout	22000	USD
	ekso	Shares Issued Capital Contribution SharesIssuedCapitalContribution	508000	USD
	ekso	Shares Issued Capital Contribution SharesIssuedCapitalContribution	191000	USD
CY2018Q3	ekso	Stock Issued During Period Value Equiposis Supply And Sales Earnouts StockIssuedDuringPeriodValueEquiposisSupplyAndSalesEarnouts	1000	USD
CY2019Q1	ekso	Stock Issued During Period Value Equiposis Supply And Sales Earnouts StockIssuedDuringPeriodValueEquiposisSupplyAndSalesEarnouts	22000	USD
CY2016Q4	ekso	Success Fee Expenses SuccessFeeExpenses	250000	USD
	ekso	Transfer Of Property And Equipment From Inventory TransferOfPropertyAndEquipmentFromInventory	757000	USD
	ekso	Transfer Of Property And Equipment From Inventory TransferOfPropertyAndEquipmentFromInventory	-195000	USD
CY2018Q4	ekso	Contract With Customers Liability Customer Deposits And Advances ContractWithCustomersLiabilityCustomerDepositsAndAdvances	62000	USD
CY2019Q3	ekso	Contract With Customers Liability Customer Deposits And Advances ContractWithCustomersLiabilityCustomerDepositsAndAdvances	73000	USD
CY2019Q3	ekso	Debt Covenant Covenant Compliance Unrestricted Cash DebtCovenantCovenantComplianceUnrestrictedCash	4372000	USD
CY2018Q4	ekso	Deferred Device Revenue DeferredDeviceRevenue	70000	USD
CY2019Q3	ekso	Deferred Device Revenue DeferredDeviceRevenue	47000	USD
CY2018Q4	ekso	Deferred Extended Maintenance And Support DeferredExtendedMaintenanceAndSupport	2114000	USD
CY2019Q3	ekso	Deferred Extended Maintenance And Support DeferredExtendedMaintenanceAndSupport	2826000	USD
CY2018Q4	ekso	Deferred Royalties DeferredRoyalties	300000	USD
CY2019Q3	ekso	Deferred Royalties DeferredRoyalties	290000	USD
	ekso	Gain Loss On Change In Fair Value Contingent Liabilities GainLossOnChangeInFairValueContingentLiabilities	13000	USD
	ekso	Gain Loss On Change In Fair Value Contingent Liabilities GainLossOnChangeInFairValueContingentLiabilities	19000	USD
CY2018Q3	ekso	Gain Loss On Warrant Liability GainLossOnWarrantLiability	-681000	USD
	ekso	Gain Loss On Warrant Liability GainLossOnWarrantLiability	-162000	USD
CY2019Q3	ekso	Gain Loss On Warrant Liability GainLossOnWarrantLiability	4430000	USD
	ekso	Gain Loss On Warrant Liability GainLossOnWarrantLiability	6045000	USD
CY2018Q3	ekso	Gain Loss On Warrant Modification GainLossOnWarrantModification	0	USD
	ekso	Gain Loss On Warrant Modification GainLossOnWarrantModification	0	USD
CY2019Q3	ekso	Gain Loss On Warrant Modification GainLossOnWarrantModification	0	USD
	ekso	Gain Loss On Warrant Modification GainLossOnWarrantModification	-257000	USD
	ekso	Operating Lease Base Rent OperatingLeaseBaseRent	32000	USD
	ekso	Operating Leases Liability Initial Recognition OperatingLeasesLiabilityInitialRecognition	1498000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3156000	USD
CY2019Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1362000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3660000	USD
CY2019Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5206000	USD
CY2018Q3	us-gaap	Accretion Expense AccretionExpense	19000	USD
	us-gaap	Accretion Expense AccretionExpense	64000	USD
CY2019Q3	us-gaap	Accretion Expense AccretionExpense	11000	USD
	us-gaap	Accretion Expense AccretionExpense	40000	USD
CY2019Q3	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	4000	USD
CY2018Q4	us-gaap	Assets Assets	17655000	USD
CY2019Q3	us-gaap	Assets Assets	20292000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	14967000	USD
CY2019Q3	us-gaap	Assets Current AssetsCurrent	17034000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27813000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	16000	USD
CY2018Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9577000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9577000	shares
CY2019Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14618000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14646000	shares
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3541000	USD
CY2019Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2589000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-92000	USD
CY2019Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	274000	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	173903000	USD
CY2019Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	186629000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	892000	USD
CY2018Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	402000	USD
CY2018Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	938000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	636000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	557000	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	487000	USD
CY2018Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	938000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2232000	USD
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	487000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1680000	USD
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	128000	USD
CY2019Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	128000	USD
CY2018Q3	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	7000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	25000	USD
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12995000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7655000	USD
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8058000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-14818000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	403000	USD
CY2018Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	3396000	shares
CY2019Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	8559000	shares
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	141429000	shares
CY2019Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	141429000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	62963000	shares
CY2019Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	74953000	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	63000	USD
CY2019Q3	us-gaap	Common Stock Value CommonStockValue	75000	USD
CY2019Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	74953000	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	62963000	shares
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6939000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22703000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	530000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9045000	USD
CY2018Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2597000	USD
CY2019Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	3244000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1102000	USD
CY2019Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1398000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1495000	USD
CY2019Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1846000	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	1366000	USD
CY2019Q3	us-gaap	Contractual Obligation ContractualObligation	845000	USD
CY2019Q3	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	50000	USD
CY2018Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1467000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5217000	USD
CY2019Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1569000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5288000	USD
CY2019Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	3356000	USD
CY2019Q3	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.1020
	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.1037
CY2019Q3	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	51000	USD
CY2018Q4	us-gaap	Deferred Revenue Leases Net DeferredRevenueLeasesNet	51000	USD
CY2019Q3	us-gaap	Deferred Revenue Leases Net DeferredRevenueLeasesNet	8000	USD
CY2018	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.5
	us-gaap	Depreciation Depreciation	1174000	USD
	us-gaap	Depreciation Depreciation	519000	USD
	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	119000	USD
	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	75000	USD
CY2018Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	585000	USD
CY2019Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	2131000	USD
CY2018Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.38
CY2019Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2018Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.38
CY2019Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-133000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-30000	USD
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2446000	USD
CY2019Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1816000	USD
CY2018Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	35000	USD
CY2019Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	30000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-291000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-384000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-126000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2018Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2785000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9350000	USD
CY2019Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1593000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6030000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	189000	USD
CY2019Q3	us-gaap	Goodwill Goodwill	189000	USD
CY2019Q1	us-gaap	Grants Receivable GrantsReceivable	1500000	USD
CY2018Q3	us-gaap	Gross Profit GrossProfit	1083000	USD
	us-gaap	Gross Profit GrossProfit	2819000	USD
CY2019Q3	us-gaap	Gross Profit GrossProfit	1750000	USD
	us-gaap	Gross Profit GrossProfit	4909000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	8000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1058000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1772000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	109000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1608000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	477000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-185000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	557000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	647000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1254000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-195000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-831000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-95000	USD
CY2018Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2019Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	13000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2018Q3	us-gaap	Interest Expense InterestExpense	145000	USD
	us-gaap	Interest Expense InterestExpense	469000	USD
CY2019Q3	us-gaap	Interest Expense InterestExpense	88000	USD
	us-gaap	Interest Expense InterestExpense	316000	USD
CY2018Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	141000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	462000	USD
CY2019Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	83000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	303000	USD
CY2018Q3	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	106000	USD
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	343000	USD
CY2019Q3	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	63000	USD
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	228000	USD
	us-gaap	Interest Paid Net InterestPaidNet	350000	USD
	us-gaap	Interest Paid Net InterestPaidNet	255000	USD
CY2018Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	730000	USD
CY2019Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	346000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	3371000	USD
CY2019Q3	us-gaap	Inventory Net InventoryNet	3342000	USD
CY2018Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	2310000	USD
CY2019Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	2735000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	513000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	126000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	175000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2019Q3	us-gaap	Lessor Operating Lease Term Of Contract LessorOperatingLeaseTermOfContract	P12M
CY2018Q4	us-gaap	Liabilities Liabilities	14927000	USD
CY2019Q3	us-gaap	Liabilities Liabilities	13871000	USD
CY2018Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	331000	USD
CY2019Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	261000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	161000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	29000	USD
CY2018Q3	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
CY2019Q3	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	706000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1398000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	231000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	528000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17655000	USD
CY2019Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	20292000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10132000	USD
CY2019Q3	us-gaap	Liabilities Current LiabilitiesCurrent	8087000	USD
CY2019Q3	us-gaap	Long Term Debt LongTermDebt	3305000	USD
CY2019Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	2333000	USD
CY2019Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	440000	USD
CY2019Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	2333000	USD
CY2019Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	583000	USD
CY2019Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	972000	USD
CY2018Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	2648000	USD
CY2019Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	972000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2377000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14770000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-51000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-60000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17011000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14277000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-7899000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-7978000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-6983000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-22860000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-6551000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-3066000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	206000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-9411000	USD
CY2018Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6983000	USD
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	7177000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-22860000	USD
CY2019Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	206000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9411000	USD
CY2018Q4	us-gaap	Notes Payable Current NotesPayableCurrent	2333000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3790000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-13800000	USD
CY2018Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	130000	USD
CY2019Q3	us-gaap	Notes Payable Current NotesPayableCurrent	2333000	USD
	us-gaap	Operating Expenses OperatingExpenses	24710000	USD
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	5540000	USD
	us-gaap	Operating Expenses OperatingExpenses	18709000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6094000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-21891000	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	589000	USD
CY2019Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	134000	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	404000	USD
	us-gaap	Operating Lease Lease Income OperatingLeaseLeaseIncome	509000	USD
CY2019Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	1223000	USD
CY2018Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	USD
CY2019Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	405000	USD
CY2018Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2019Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	818000	USD
CY2018Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	USD
CY2019Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1174000	USD
CY2019Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.105
CY2019Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y8M9D
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	256000	USD
CY2019Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	135000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	134000	USD
CY2019Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	172000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-207000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	320000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	44000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	148000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-106000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	324000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	44000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	157000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	324000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	366000	USD
CY2018Q4	us-gaap	Other Employee Related Liabilities Current OtherEmployeeRelatedLiabilitiesCurrent	270000	USD
CY2019Q3	us-gaap	Other Employee Related Liabilities Current OtherEmployeeRelatedLiabilitiesCurrent	0	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	67000	USD
CY2019Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	17000	USD
CY2018Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-889000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-969000	USD
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3996000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4389000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	51000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	60000	USD
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2019Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	63000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1585000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1783000	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1282000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4479000	USD
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1149000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4032000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.06
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-171146000	USD
CY2019Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	281000	USD
CY2019Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	428000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3961000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	16325000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	228000	USD
CY2018Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	307000	USD
CY2019Q3	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	307000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2365000	USD
CY2019Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1723000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-119000	USD
CY2019Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-180557000	USD
CY2018Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2550000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	8036000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	3319000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	10197000	USD
CY2019Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	354000	USD
CY2019Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	1074000	USD
CY2019Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	1743000	USD
CY2019Q3	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P3M
CY2019Q3	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2019Q3	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
CY2018Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3106000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	10892000	USD
CY2019Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2818000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	8666000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2232000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1680000	USD
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.04
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.02
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0212
CY2016Q4	us-gaap	Share Price SharePrice	8.00
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2018Q1	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	190000	USD
CY2018Q2	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	40000	USD
CY2019Q2	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	919000	USD
	us-gaap	Stock Issued1 StockIssued1	230000	USD
	us-gaap	Stock Issued1 StockIssued1	919000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	508000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	191000	USD
CY2018Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3961000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	7305000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2393000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-62000	USD
CY2018Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	55000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	173000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	21391000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	14841000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	7626000	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	5587000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	2728000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	4534000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	5404000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	6421000	USD
CY2018Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61381000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60721000	shares
CY2019Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	74951000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	70263000	shares
CY2018Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61381000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60721000	shares
CY2019Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	74938000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	70263000	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk and Other Risks and Uncertainties</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and accounts receivable. The Company maintains its cash accounts in excess of federally insured limits. However, the Company believes it is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. The Company extends credit to customers, most of which are hospitals or other large nationally recognizable institutions, in the normal course of business. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the condensed consolidated financial statements. The Company does not require collateral from its customers to secure accounts receivable.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable are derived from the sale of products shipped to and services performed for customers. Invoices are aged based on contractual terms with the customer. The Company reviews accounts receivable for collectability and records an allowance for credit losses, as needed. The Company has not experienced any material losses related to accounts receivable as of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency. The Company does not enter into any foreign currency hedging agreements and is susceptible to gains and losses from foreign currency fluctuations. To date, the Company has not experienced significant gains or losses upon settling foreign currency denominated accounts receivable.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company had </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> customer with an accounts receivable balance totaling </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;"> or more of the Company’s total accounts receivable (</font><font style="font-family:inherit;font-size:10pt;">28%</font><font style="font-family:inherit;font-size:10pt;">), as compared with one customer at </font><font style="font-family:inherit;font-size:10pt;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> (</font><font style="font-family:inherit;font-size:10pt;">19%</font><font style="font-family:inherit;font-size:10pt;">).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company had </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> customer with sales of </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;"> or more of the Company’s total revenue (</font><font style="font-family:inherit;font-size:10pt;">12%</font><font style="font-family:inherit;font-size:10pt;">), as compared with </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> customers in the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company had </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> customer with sales of </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;"> or more of the Company’s total revenue (</font><font style="font-family:inherit;font-size:10pt;">19%</font><font style="font-family:inherit;font-size:10pt;">), as compared with </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> customers in the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but are not limited to, revenue recognition, deferred revenue and the deferral of the associated costs, the valuation of warrants and employee stock options, future warranty costs, accounting for leases, useful lives assigned to long-lived assets, valuation of inventory, realizability of deferred tax assets, and contingencies. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001549084-19-000007-index-headers.html	Edgar Link	pending
0001549084-19-000007-index.html	Edgar Link	pending
0001549084-19-000007.txt	Edgar Link	pending
0001549084-19-000007-xbrl.zip	Edgar Link	pending
ekso-20190930.xml	Edgar Link	completed
ekso-20190930.xsd	Edgar Link	pending
ekso-20190930_cal.xml	Edgar Link	unprocessable
ekso-20190930_def.xml	Edgar Link	unprocessable
ekso-20190930_lab.xml	Edgar Link	unprocessable
ekso-20190930_pre.xml	Edgar Link	unprocessable
ekso-93019x10q.htm	Edgar Link	pending
ekso-93019xex311.htm	Edgar Link	pending
ekso-93019xex312.htm	Edgar Link	pending
ekso-93019xex321.htm	Edgar Link	pending
ekso-93019xex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EKSO
EKSO BIONICS HOLDINGS, INC. Stock $ekso

2019 Q4 Form 10-Q Financial Statement

#000154908419000007 Filed on October 30, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EKSO EKSO BIONICS HOLDINGS, INC. Stock $ekso

2019 Q4 Form 10-Q Financial Statement

#000154908419000007 Filed on October 30, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EKSO
EKSO BIONICS HOLDINGS, INC. Stock $ekso